Reading INMB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INMB free→Reading INMB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INMB free→QuarterlyIQ Insights · INMB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November…
Entry into a Material Definitive Agreement. On December 22, 2025, INmune Bio Inc. (the “Company”) entered into an amendment (the “Warrant Amendment”) with certain holders of warrants previously issued by the Company in its April 2024 offerings on April 24, 2024 and April 29, 2024, respectively (the “April 2024 Warrants”). The exercise price of an aggregate of 1,348,315 outstanding April 2024 Warrants was (i) reduced to $1.95, which price is greater than Minimum Price (as defined in Nasdaq Lis…
Entry into a Material Definitive Agreement. On December 19, 2025, INmune Bio Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through A.G.P., up to $65,000,000 of shares of its common stock, par value $0.001 per share (the “Common Stock”). The Company is not obligated to sell any shares of Common Stock under the Sales Agreement. Subje…
Termination of a Material Definitive Agreement. As previously disclosed, on August 9, 2024, INmune Bio Inc. (the “Company”) entered into an Amended and Restated At-The-Market Sales Agreement (the “Sales Agreement”) with RBC Capital Markets, LLC (“RBC”) and BTIG, LLC (“BTIG”), pursuant to which the Company could offer and sell shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate offering price of up to $75,000,000, from time to time through RBC and BTIG…
Material Modification to Rights of Security Holders The information set forth under “
Entry into a Material Definitive Agreement. On December 5, 2025, INmune Bio Inc. (the “Company”) entered into Amendment No. 5 (the “Amendment”) to the Rights Agreement, dated as of December 30, 2020, between the Company and VStock Transfer, LLC, as Rights Agent, as amended (the “Rights Agreement”). The Amendment extended the expiration of the Rights Agreement to December 31, 2026 and provides that such expiration date will automatically extend for successive one-year terms, unless the Company…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 2, 2025, INmune Bio Inc. (the “Company”) and David J. Moss, the Company’s President and Chief Executive entered into an amendment to Mr. Moss’s employment agreement, dated November 26, 2025, to correct a mistake in the original agreement, restating his base salary to $454,000 per annum and restating his option grant under the Second Ame…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Moss Employment Agreement On November 26, 2025, INmune Bio Inc. (the “Company”) and David J. Moss, the Company’s President and Chief Executive entered into an employment agreement. Pursuant to the employment agreement, beginning on November 1, 2025, Mr. Moss will be paid a base salary of $500,000 per annum and is eligible to receive an annual discr…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 18, 2025 (the “Repricing Date”), INmune Bio Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”) in a virtual meeting format via live webcast. As further described in
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.
Entry into a Material Definitive Agreement. On June 27, 2025, INmune Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with two healthcare-focused institutional investors for the sale of an aggregate of 3,000,000 shares of common stock, par value $0.001 per share (the “Shares”), in a registered direct offering (the “Offering”) at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules, for aggregate gross proceeds to the Com…
Other Events. On June 10, 2025, the Company issued a press release announcing the Company’s collaboration with Kirsty Dixon PhD, Assoc Prof. of Surgery at Virginia Commonwealth University in Richmond, Virginia on the interaction of traumatic brain injury and Alzheimer's disease.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As noted in
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.
Changes in Registrant’s Certifying Accountant. (a) Resignation of Independent Registered Public Accounting Firm On November 1, 2024, CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum LLP (“Marcum”). On May 7, 2025, INmune Bio Inc. (the “Company”) dismissed Marcum as the Company’s independent registered public accounting firm as a result of such acquisition, and the Company’s audit committee approved the dismissal. The audit report of Marcum on the Company’s consolidated fina…
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Termination of a Material Definitive Agreement. On February 6, 2025, the Company and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“SVB”) entered into a letter agreement pursuant to which the Company and SVB terminated the Loan and Security Agreement (the “Loan Agreement”) dated as of June 10, 2021, by and between the Company, as borrower, and SVB as administrative agent, collateral agent and lender and SVB Innovation Credit Fund VIII, L.P., as a lender, pursuant to…
Entry into a Material Definitive Agreement. On February 6, 2025, INmune Bio Inc. (the “Company”) and Great Ormond Street Hospital NHS Foundation Trust (“GOSH”) entered into a license agreement (the “License Agreement”) for the exclusive commercial use to clinical trial data associated with the Mission EB study (the “Mission EB study”) investigating the potential of CORDStrom to treat recessive dystrophic epidermolysis bullosa (“RDEB”) in pediatric patients. The Company owns the intellectual p…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.